Jessica R. Berman, MD

Appointments

Assistant Attending Physician, Hospital for Special Surgery

Instructor in Medicine, Weill Medical College of Cornell University

Specialty
Rheumatology

Certification

Internal Medicine, 2001

Rheumatology, 2002

State Licensure
New York

Education

MD, Harvard Medical School, US

Residency

Beth Israel Deaconess Hospital, Boston, Massachusetts, US

Fellowship

Hospital for Special Surgery, US

Jessica R. Berman, MD is the author of the following articles on HSS.edu:

For Patients

• Undifferentiated Connective Tissue Disease - In-Depth Overview
• Can better social support improve your health in SLE?
• What is Arthritis?

Special Expertise

Systemic Lupus Erythematosus

Rheumatoid Arthritis

Mixed and Undifferentiated connective tissue diseases

Awards

Phi Beta Kappa, Vassar College, 1988

Selected Publications

Berman J, Girardi G, Salmon J. TNF-alpha Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss. Journal of Immunology 2005, 174: 485-490.

Berman J, Erkan D and Lockshin M. A Patient’s Guide to the Antiphospholipid Antibody Syndrome. The Antiphospholipid Syndrome. R.A. Asherton, R. Cervera, J.-C. Piette and Y Shoenfeld, editors. Elsevier Science B.V., 2002: 395-402

Girardi G, Berman J, Redecha P, Spruce L, Thurman JM, Kraus D, Hollmann TJ, Casali P, Caroll MC, Wetsel RA, Lambris JD. Holers VM. Salmon JE. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal of Clinical Investigation. 112(11):1644-54.

Erkan D, Leibowitz E, Berman J, Lockshin M. Perioperative Medical Management of Antiphospholipid Syndrome: Hospital for Special Surgery Experience, Review of Literature and Recommendations. J Rheum 2002; 29: 843-9

For more publications, please see the PubMed listing.

Clinical Trials

• A Phase 1b Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation study with an open-label extension to evaluate the safety and tolerability of multiple IV doses of Medi-545, a fully Human Anti-interferon-alpha Monoclonal Antibody,
• A Phase I, Randomized, Double-blind, Placebo-controlled, Escalating Single- and Multiple-dose Study of the Safety, Tolerability, and Pharmakokinetics of RhuMab IFN alpha in Adults with Systemic Lupus Erythematosus
• The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study
• A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids
• A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study To Evaluate Safety And Tolerability Of A Single IV Dose Of MEDI-545, A Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes